| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Upon UV irradiation, the aryl azide generates a reactive nitrene that forms covalent bonds with nearby residues in ATP-binding sites of kinases and other ATP-binding proteins. This allows capture and identification of protein-protein interactions and ATP-binding partners. No direct pharmacological target.
|
|---|---|
| ln Vitro |
No direct biological activity as a drug. Used as a chemical probe for photoaffinity labeling. In cell lysates or purified systems, ATP-ArN3 labels ATP-binding proteins upon UV activation. Binding specificity depends on the target protein; used to map interaction interfaces.
|
| ln Vivo |
No in vivo activity; UV activation limits use to in vitro applications. Not suitable for live cell labeling due to UV toxicity and poor penetration. Used in cell lysates or permeabilized cells. No therapeutic applications.
|
| Enzyme Assay |
Photoaffinity labeling protocol: Purified kinase (0.1-1 microM) or cell lysate (50-200 microg protein) mixed with ATP-ArN3 (10-100 microM) in kinase buffer (20 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM DTT) on ice. Pre-incubated in dark for 10-30 min. Transfer to 96-well plate and irradiate with UV (254 or 365 nm) for 5-20 min at distance 1-2 cm. Quench with DTT (50 mM). Analyze by SDS-PAGE and autoradiography or Western blot (anti-ATP-ArN3 antibody if available). For identification, excise gel bands, trypsin digest, LC-MS/MS.
|
| Cell Assay |
Cell lysate crosslinking: HeLa or HEK293T cells lysed in photoaffinity labeling buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, protease inhibitors). Clarified lysate (1-5 mg/mL protein). Add ATP-ArN3 (50 microM), pre-incubate dark at 4degC for 30 min. Transfer to 96-well plate, irradiate UV (365 nm) for 10-15 min. Denature with SDS-PAGE loading buffer, separate by electrophoresis. Excise bands, MS analysis.
|
| Animal Protocol |
No in vivo protocol due to UV requirement. For cell-based studies, cells can be permeabilized or lysed before UV irradiation. Not applicable for animal models.
|
| ADME/Pharmacokinetics |
Not a drug; in vitro reagent only. No PK data. ATP derivatives are anionic and cell-impermeant; used in lysed systems. No absorption, distribution, or elimination data.
|
| Toxicity/Toxicokinetics |
No toxicological data as research reagent. UV irradiation hazard: UV light can cause eye and skin damage; use UV-protective eyewear and shielding. Standard lab precautions: gloves, lab coat, goggles. Store powder at -20degC, avoid moisture.
|
| References | |
| Additional Infomation |
ATP-ArN3 is a research-grade UV-activatable ATP crosslinking analog used to study ATP-binding proteins, kinase-substrate interactions, and protein-nucleotide interfaces. Not a drug; no approved therapeutic use.
|
| Molecular Formula |
C23H33N10O15P3
|
|---|---|
| Molecular Weight |
782.49
|
| CAS # |
1224198-85-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~25.56 mM; with sonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2780 mL | 6.3899 mL | 12.7797 mL | |
| 5 mM | 0.2556 mL | 1.2780 mL | 2.5559 mL | |
| 10 mM | 0.1278 mL | 0.6390 mL | 1.2780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
